Advertisement

Topics

Polyethylene Glycol 3350, NF Powder for Oral Solution | POLYETHYLENE GLYCOL 3350 [Physicians Total Care, Inc.] | BioPortfolio

13:40 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Rx Only

A white powder for reconstitution. Polyethylene Glycol 3350, NF Powder for Oral Solution is a synthetic polyglycol having an average molecular weight of 3350. The actual molecular weight is not less than 90.0 percent and not greater than 110.0 percent of the nominal value. The chemical formula is HO(C2H4O)nH in which n represents the average number of oxyethylene groups. Below 55°C, it is a free flowing white powder freely soluble in water. Polyethylene Glycol 3350, NF is an osmotic agent for the treatment of constipation.

Polyethylene Glycol 3350, NF is an osmotic agent which causes water to be retained with the stool. Essentially, complete recovery of Polyethylene Glycol 3350, NF was shown in normal subjects without constipation. Attempts at recovery of Polyethylene Glycol 3350, NF in constipated patients resulted in incomplete and highly variable recovery. In vitro study showed indirectly that Polyethylene Glycol 3350, NF was not fermented into hydrogen or methane by the colonic microflora in human feces. Polyethylene Glycol 3350, NF appears to have no effect on the active absorption or secretion of glucose or electrolytes. There is no evidence of tachyphylaxis.

In one study, patients with less than 3 bowel movements per week were randomized to Polyethylene Glycol 3350, NF, 17 grams, or placebo for 14 days. An increase in bowel movement frequency was observed for both treatment groups during the first week of treatment. Polyethylene Glycol 3350, NF was statistically superior to placebo during the second week of treatment.

In another study, patients with 3 bowel movements or less per week and/or less than 300 grams of stool per week were randomized to 2 dose levels of Polyethylene Glycol 3350, NF or placebo for 10 days each. Success was defined by an increase in both bowel movement frequency and daily stool weight. For both parameters, superiority of the 17 gram dose of Polyethylene Glycol 3350, NF over placebo was demonstrated.

For the treatment of occasional constipation. This product should be used for 2 weeks or less or as directed by a physician.

Polyethylene Glycol 3350, NF is contraindicated in patients with known or suspected bowel obstruction and patients known to be allergic to polyethylene glycol.

Patients with symptoms suggestive of bowel obstruction (nausea, vomiting, abdominal pain or distention) should be evaluated to rule out this condition before initiating Polyethylene Glycol 3350, NF therapy.

Patients presenting with complaints of constipation should have a thorough medical history and physical examination to detect associated metabolic, endocrine and neurogenic conditions, and medications. A diagnostic evaluation should include a structural examination of the colon. Patients should be educated about good defecatory and eating habits (such as high fiber diets) and lifestyle changes (adequate dietary fiber and fluid intake, regular exercise) which may produce more regular bowel habits.

Polyethylene Glycol 3350, NF should be administered after being dissolved in approximately 4 - 8 ounces of water, juice, soda, coffee, or tea.

Polyethylene Glycol 3350, NF softens the stool and increases the frequency of bowel movements by retaining water in the stool. It should always be taken by mouth after being dissolved in 4 - 8 ounces of water, juice, soda, coffee, or tea. Should unusual cramps, bloating, or diarrhea occur, consult your physician.

Two to 4 days may be required to produce a bowel movement. This product should be used for 2 weeks or less or as directed by a physician. Prolonged, frequent or excessive use of Polyethylene Glycol 3350, NF may result in electrolyte imbalance and dependence on laxatives.

No clinically significant effects on laboratory tests have been demonstrated.

No specific drug interactions have been demonstrated.

Long-term carcinogenicity studies, genetic toxicity studies and reproductive toxicity studies in animals have not been performed with Polyethylene Glycol 3350, NF.

Animal reproductive studies have not been performed with Polyethylene Glycol 3350, NF. It is also not known whether Polyethylene Glycol 3350, NF can cause fetal harm when administered to a pregnant woman, or can affect reproductive capacity. Polyethylene Glycol 3350, NF should only be administered to a pregnant woman if clearly needed.

Safety and effectiveness in pediatric patients has not been established.

There is no evidence for special considerations when Polyethylene Glycol 3350, NF is administered to elderly patients.

In geriatric nursing home patients, a higher incidence of diarrhea occurred at the recommended 17 gram dose. If diarrhea occurs, Polyethylene Glycol 3350, NF should be discontinued.

Nausea, abdominal bloating, cramping and flatulence may occur. High doses may produce diarrhea and excessive stool frequency, particularly in elderly nursing home patients.

Patients taking other medications containing polyethylene glycol have occasionally developed urticaria suggestive of an allergic reaction.

There have been no reports of accidental overdosage. In the event of overdosage, diarrhea would be the expected major event. If an overdose of drug occurred without concomitant ingestion of fluid, dehydration due to diarrhea may result. Medication should be terminated and free water administered. The oral LD is >50 gm/kg in mice, rats and rabbits.

The usual dose is 17 grams (about 1 heaping tablespoonful) of powder per day (or as directed by physician) in 4 - 8 ounces of water, juice, soda, coffee, or tea. Each bottle of Polyethylene Glycol 3350, NF is supplied with a dosing cap marked to contain 17 grams of laxative powder when filled to the indicated line.

Two to 4 days (48 to 96 hours) may be required to produce a bowel movement.

In powdered form, for oral administration after dissolution in water, juice, soda, coffee, or tea. Polyethylene Glycol 3350, NF Powder for Oral Solution is available in two package sizes: a 16 oz. container of 255 grams of laxative powder (NDC 54868-5160-1) and a 24 oz. container of 527 grams of laxative powder (NDC 54868-5160-0).

The dosing cap supplied with each bottle is marked with a measuring line and may be used to measure a single Polyethylene Glycol 3350, NF dose of 17 grams (about 1 heaping tablespoonful).

Store at 20° - 25°C (68° - 77°F); excursions permitted between 15° - 30°C (59° - 86°F) [See USP Controlled Room Temperature].

Distributed by: Kremers Urban Pharmaceuticals Inc. Princeton, NJ 08540, USA

Rev. 1E 08/11

Additional barcode labeling by: Physicians Total Care, Inc.Tulsa, Oklahoma       74146

Keep this and other drugs out of reach of children.

Store at 20° – 25°C (68° – 77°F); excursions permitted between 15° – 30°C (59° – 86°F) [See USP Controlled Room Temperature].

Distributed by:Kremers Urban Pharmaceuticals Inc.Princeton, NJ 08540, USA

Rev. 1E 08/11

PATIENT INFORMATION

Polyethylene Glycol 3350, NF Powder for Oral Solution is a prescription only laxative which has been prescribed by your physician to treat constipation. This product should only be used by the person for whom it was prescribed.

How to take

The dose is 17 grams each day or as directed by physician. It should always be taken by mouth. Measure the dose using the dosing cap (or use one heaping tablespoonful of powder), stir and dissolve in a glass (4 - 8 oz.) of water, juice, soda, coffee, or tea. Taking more than the prescribed dose may cause loss of fluid due to severe diarrhea.

How will it work

Polyethylene Glycol 3350, NF softens the stool and increases the frequency of bowel movements by retaining water in the stool. Your first bowel movement will usually happen in two to four days, although results may vary for individual patients.

How long should I take it

Polyethylene Glycol 3350, NF achieves its best results when used between one and two weeks. You may discontinue taking the drug after you have had several satisfactory bowel movements. Should unusual cramps, bloating, or diarrhea occur, consult your physician. Polyethylene Glycol 3350, NF is intended for up to a two week course of therapy. You should not use for a longer time unless directed by your physician.

Next Steps

After successfully completing the Polyethylene Glycol 3350, NF therapy (usually between one and two weeks), please discuss with your physician lifestyle changes which may produce more regular bowel habits (adequate dietary and fluid intake, regular exercise).

Who Should NOT take Polyethylene Glycol 3350, NF

Polyethylene Glycol 3350, NF should not be used by children. It should not be used by pregnant women unless prescribed by a physician.

Side Effects/Drug Reactions

Occasionally, Polyethylene Glycol 3350, NF may cause nausea, stomach fullness, cramping, diarrhea and/or gas. Do not take if you have symptoms such as nausea, vomiting, abdominal pain or distention, which may be due to bowel obstruction. On rare occasions, hives and skin rashes have been reported which are suggestive of an allergic reaction. If you get an allergic reaction, you should discontinue the medication and call your physician.

If you are allergic to polyethylene glycol, do not use this drug product.

Distributed by: Kremers Urban Pharmaceuticals Inc. Princeton, NJ 08540, USA

NDC 54868-5160-1

PRESCRIPTION LAXATIVE

Polyethylene Glycol 3350, NFPowder for Oral Solution

This bottle contains255 grams of polyethylene glycol 3350, NF powder

Rx Only

Manufacturer

Physicians Total Care, Inc.

Active Ingredients

Source

Drugs and Medications [225 Associated Drugs and Medications listed on BioPortfolio]

Benzo-jel [henry schein, inc.]

Benzo-Jel™ Unit Dose

Polyethylene glycol 3350 [emcure pharmaceuticals usa inc.]

Drug FactsActive ingredient (in each dose)Polyethylene Glycol 3350, 17 g (cap filled to line)PurposeOsmotic Laxative

Polyethylene glycol 3350 [atlantic biologicals corps]

Polyethylene Glycol 3350 NF Polyethylene Glycol 3350 Powder for Oral Solution

Polyethylene glycol 3350 [proficient rx lp]

Polyethylene Glycol 3350 NF Polyethylene Glycol 3350 Powder for Oral Solution

Polyethylene glycol 3350 [lake erie medical & surgical supply dba quality care products llc]

Polyethylene Glycol 3350 NF Polyethylene Glycol 3350 Powder for Oral Solution

Clinical Trials [272 Associated Clinical Trials listed on BioPortfolio]

Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(COMPLETED)

Randomized, placebo-controlled, double blind study. 203 subjects entered the study to compare the effect on occasional constipation of polyethylene glycol 3350 to placebo. Subjects took on...

Preference of Tegaserod vs. PEG 3350 in Patients With Constipation

To determine whether female patients have a preference for tegaserod of PEG 3350 relative to dosage form, convenience, ease of administration and taste

Polyethylene Glycol Versus Low Volume Solutions Prior to Colonoscopy

Study evaluates the efficacy and tolerability of low volume preparations compared with conventional 4L polyethylene glycol prior to colonoscopy

Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer

This randomized phase II trial studies how well macrogol 3350-based oral osmotic laxative (polyethylene glycol 3350) works in preventing cancer in patients at risk of colorectal cancer. Ch...

Observational Study of Methoxy Polyethylene Glycol Epoetin Beta Daily Use in Participants on Peritoneal Dialysis

This non-interventional, observational study investigates the efficacy, safety and usability of methoxy polyethylene glycol epoetin beta in participants on peritoneal dialysis. Participant...

PubMed Articles [762 Associated PubMed Articles listed on BioPortfolio]

PEG 3350 Versus Lactulose for Treatment of Functional Constipation in Children: Randomized Study.

The aim of this study was to compare the clinical efficacy and tolerance of polyethylene glycol 3350 (PEG) and lactulose for the treatment of functional constipation in infants and children.

Bowel Preparation for Colonoscopy in Children: 1 Day PEG-3350 with Bisacodyl versus 3 Day Sennosides.

Bowel preparation (BP) for colonoscopy is a challenging procedure in children and different regimens have been used for this purpose. Polyethylene glycol (PEG) is the most preferred agent in recent ye...

Bowel Preparation With Polyethylene Glycol 3350 or Fasting Only Before Peroral Single-balloon Enteroscopy: A Randomized European Multicenter Trial.

Although bowel preparation before colonoscopy and capsule endoscopy is widely evaluated and usually follows established guidelines, a standard preparation regime for peroral small bowel enteroscopy is...

Effects of Polyethylene Glycol-20k on Postresuscitation Myocardial and Cerebral Function in a Rat Model of Cardiopulmonary Resuscitation.

Polyethylene glycol-20k is a hybrid cell impermeant that reduces ischemia injury and improves microcirculatory flow during and following low flow states through nonenergy-dependent water transfer in t...

Single-Dose Linaclotide Is Equal in Efficacy to Polyethylene Glycol for Bowel Preparation Prior to Capsule Endoscopy.

Video capsule endoscopy provides noninvasive visualization of the small bowel, but yield is often limited by debris. At our institution, preparation with polyethylene glycol (PEG) and simethicone is u...

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pain Disorder
Pain is a feeling (sharp or dull) triggered in the nervous system which can be transient or constant. Pain can be specific to one area of the body eg back, abdomen or chest or more general all over the body eg muscles ache from the flu. Without pain ...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record